Vaxart, Inc. VXRT

I did not sell on Feb 2nd, but I learned my lesson on the hard way, “too good to be true, take at least 50% “. We are the best stop loss ?

In canada , the virus is beginning to change , other forms, other power , new kind of ghost, this is only the beginning of this bio new world ...

Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity https://seekingalpha.com/article/4403369-vaxart-stock-drop-following-phase-1-data-for-oral-covidminus-19-vaccine-is-buying-opportunity

It’s all same old crap of scaring away the little guy. I continue adding up at these rates. Sky is the limit.

ALYI Welcomes Elon Musk And Tesla To Texas – Now How About Joining Us In Africa Too?
December 11, 2020 Stock Day Media 592 Views ALYI, elonmusk, Elonmusknews, tesla
PR Newswire

DALLAS, Dec. 11, 2020

DALLAS, Dec. 11, 2020 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI), an electric vehicle innovation company headquartered in Dallas, Texas, today welcomed Elon Musk and Tesla to Texas.

Not only that the lake of neutralising antibodies (specific to the corona virus) were not found on the participants who took a single doses only of the vaccine, but also have to be said that, however, they was found in nasal swab samples of the participants who received two doses...
What is the different between this vaccine and those of Pfizer and moderna??? They also need to use two doses...
However, our uniq advantages - no need for needles and the logistic one (room temperature) - still exist.

How can someone say this results are disappointing?

We are attacked by tutes.

Keep your diamonds

In spite of absence of antibodies,Result are good !!
T-cell is the most important.
Dr tucker said next phase will start later on this Quarter!!
Holding long. Strong

Up we go

Let’s post on Twitter & soc media, lets make trending topic on VXRT ??

https://finance.yahoo.com/news/vaxart-tanks-58-oral-covid-081354958.html

I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."

Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.

First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.

Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.

Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.